





## JOINT TRANSNATIONAL CALL 2017: "Translational Research on Rare Cancers"

### PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to 

If you have any questions about this form, please do not hesitate to contact us at 

**Note:** Fields marked with a \* are mandatory

Contact Information	
First name *	Ekaterini
Last name *	Alexiou Chatzaki
Position *	Professor
Telephone number	
E-mail address*	achatzak@med.duth.gr
Website address	<a href="http://pharmacology.med.duth.gr/staff/chatzaki.html">http://pharmacology.med.duth.gr/staff/chatzaki.html</a>
Institution/Organisation *	Democritus University of Thrace
Department*	Medicine
Street	
Postal Code / City *	68100/Alexandroupolis
Country *	Greece

**\*I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

YES



## SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

### Project proposal

Project title (draft):

Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):



## OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

### Short description of the areas of interest and expertise (Max. 2000 words):

We have formed an academic **Precision Therapy** team of scientists and clinicians to identify prognostic/diagnostic/response monitoring biomarkers in liquid biopsies targeting cancer as well as other diseases. Genetic polymorphisms and epigenetic modifications as emerge in cell-free DNA is our main topic of interest. We seek to join consortia looking for pre-clinical/clinical evaluation of new diagnostic/theanostic tools towards precision/personalized treatment.

Additionally, we have a system for real-life cell monitoring (xCELLigence platform), which is a very useful tool for developing novel preclinical models and cell-based screening for cancer.

Working in close collaboration with the Oncology Clinic of the University Hospital of Alexandroupolis, Democritus University of Thrace, Greece (Prof. S. Kakolyris) and with the 4th Department of Obstetrics and Gynecology, Hippokratio Hospital of Thessaloniki, Greece (Prof. T. Agorastos), we have access to large cohorts of clinical samples and information for our projects. We could therefore contribute as either basic or clinical partner.

### Recent Selected Publications

Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, Bisgaard H, Bønnelykke K, Burchard EG, Campo P, Canino G, Carleton B, Celedón JC, Chew FT, Chiang WC, Cloutier MM, Daley D, Den Dekker HT, Dijk FN, Duijts L, Flores C, Forno E, Hawcutt DB, Hernandez-Pacheco N, de Jongste JC, Kabesch M, Koppelman GH, Manolopoulos VG, Melén E, Mukhopadhyay S, Nilsson S, Palmer CN, Pino-Yanes M, Pirmohamed M, Potočnik U, Raaijmakers JA, Repnik K, Schieck M, Sio YY, Smyth RL, Szalai C, Tantisira KG, Turner S, van der Schee MP, Verhamme KM, Maitland-van der Zee AH. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. **Pharmacogenomics**. 2017 Jul;18(10):931-943.

M Karaglani, G Ragia, M Panagopoulou, I Balgkouranidou, E Nena, G Kolios, N Papanas, VG. Manolopoulos, E Chatzaki. *Search for Pharmacoepigentic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment*. **Exp Clin Endocrinol Diabetes** 2017; 125: 1–8

Giannakopoulou E, Konstantinou F, Ragia G, Tavridou A, Karaglani M, Chatzaki E, Papapetropoulos A, Mikroulis D, Manolopoulos VG. Epigenetics-by-Sex Interaction for Coronary Artery Disease Risk Conferred by the Cystathionine  $\gamma$ -Lyase Gene Promoter Methylation. **OMICS**. 2017 21(12):741-748.

Panagopoulou M, Lambropoulou M, Balgkouranidou I, Nena E, Karaglani M, Nicolaidou C, Asimaki M, Agorastos T, Constantinidis Theoc, Constantinidis TC, Kolios G, Kakolyris S, Chatzaki E. (2016) *Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk HPV infection and cancer*. **Tumour Biol**. 2017 Apr;39(4)

Nikolaidis C, Nena E, Panagopoulou M, Balgkouranidou I, Karaglani M, Chatzaki E, Agorastos T, Constantinidis TC. *PAX1 methylation as an auxiliary biomarker for cervical cancer screening: a meta-analysis*. **Cancer Epidemiol**. 2015 Oct;39(5):682-6.

Balgkouranidou I, Matthaïos D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Tripsianis G, Chatzaki E, Lianidou ES, Kakolyris S. *Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients*. **Mutat Res**. 2015 Aug;778:46-51.

Balgkouranidou I, Karayiannakis A, Matthaïos D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, Kolios G, Kakolyris S. *Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival*. **Clin Chem Lab Med**. 2013 Jul;51(7):1505-10.

Maitland-van der Zee AH, de Boer A, Manolopoulos VG; EU-PACT Group. Genotype-guided dosing of vitamin K antagonists. **N Engl J Med**. 2014 May 1;370(18):1765-6.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. **N Engl J Med**. 2013 Dec 12;369(24):2294-303

Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. **N Engl J Med**. 2013 Dec 12;369(24):2304-12